Bill Text: TX HR127 | 2011 | 82nd Legislature 1st Special | Enrolled
Bill Title: Honoring Dr. John Mendelsohn for his 15-year tenure as president of The University of Texas M. D. Anderson Cancer Center.
Spectrum: Partisan Bill (Republican 1-0)
Status: (Passed) 2011-07-05 - Reported enrolled [HR127 Detail]
Download: Texas-2011-HR127-Enrolled.html
H.R. No. 127 |
|
||
WHEREAS, John Mendelsohn, M.D., is stepping down as president | ||
of The University of Texas M. D. Anderson Cancer Center on September | ||
1, 2011, concluding 15 years of dedicated service in which he has | ||
made significant contributions to cancer research, treatment, | ||
education, and prevention; and | ||
WHEREAS, Dr. Mendelsohn has accomplished much during his | ||
tenure, perhaps most notably growing the institution's budget and | ||
capacity to double their previous size; he has also implemented new | ||
priorities for integrated programs in patient care, research, | ||
education, and cancer prevention, and under his direction, M. D. | ||
Anderson has been named the top cancer hospital in the nation seven | ||
times in the U.S. News & World Report "America's Best Hospitals" | ||
survey; and | ||
WHEREAS, A cum laude graduate of Harvard Medical School, | ||
Dr. Mendelsohn served his residency in internal medicine at Brigham | ||
and Women's Hospital in Boston and completed fellowships at the | ||
National Institutes of Health and the Washington University School | ||
of Medicine; in 1970, he joined the faculty of the University of | ||
California San Diego, where he became the founding director of a | ||
National Cancer Institute-designated cancer center; he went on to | ||
chair the department of medicine at the Memorial Sloan-Kettering | ||
Cancer Center from 1985 to 1996 and to hold the hospital's Winthrop | ||
Rockefeller Chair in Medical Oncology; and | ||
WHEREAS, Dr. Mendelsohn's research while serving as | ||
professor and vice chair of medicine at Weill Cornell Medical | ||
College pioneered the concept of targeted anti-receptor therapy as | ||
a new form of cancer treatment; that groundbreaking work earned him | ||
the Dan David Prize in Cancer Therapy, and antibody 225 was approved | ||
by the FDA for colon cancer in 2004 and for head and neck cancer in | ||
2006; in addition, he has authored more than 250 scientific papers | ||
and articles and was the founding editor of Clinical Cancer | ||
Research for 10 years; and | ||
WHEREAS, The recipient of numerous other prestigious honors, | ||
Dr. Mendelsohn is a member of the Institute of Medicine of the | ||
National Academy of Sciences, and in 2010, he was elected as the | ||
first chair of the Worldwide Innovative Networking Consortium in | ||
Personalized Cancer Medicine; his passion remains developing and | ||
testing new cancer therapies, and he will continue his affiliation | ||
with M. D. Anderson as codirector of the new Sheikh Khalifa Bin | ||
Zayed Al Nahyan Institute for Personalized Cancer Therapy; and | ||
WHEREAS, The University of Texas M. D. Anderson Cancer Center | ||
is today among the most sophisticated and advanced cancer centers | ||
in the world, thanks in part to the far-reaching vision of Dr. John | ||
Mendelsohn, and the full impact of his exceptional leadership will | ||
continue to resonate for years to come; now, therefore, be it | ||
RESOLVED, That the House of Representatives of the 82nd Texas | ||
Legislature, 1st Called Session, hereby honor Dr. John Mendelsohn | ||
for his outstanding direction of The University of Texas M. D. | ||
Anderson Cancer Center and commend him for his lifelong commitment | ||
to medical science; and, be it further | ||
RESOLVED, That an official copy of this resolution be | ||
prepared for Dr. Mendelsohn as an expression of high regard by the | ||
Texas House of Representatives. | ||
Craddick | ||
______________________________ | ||
Speaker of the House | ||
I certify that H.R. No. 127 was adopted by the House on June | ||
28, 2011, by a non-record vote. | ||
______________________________ | ||
Chief Clerk of the House | ||